Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

This month, we spoke with Natasha B. Leighl, BSc, MMSc, MD, Medical Oncologist at the Princess Margaret Cancer Centre in Toronto, Canada. Leighl discussed the PALOMA-3 trial results, shared at the American Society of Clinical Oncology 2024 Conference. Leighl noted that the trial compared subcutaneous and intravenous administration of amivantamab for lung cancer.